Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $282.85 -2.26%
EPS Growth %: +403.1%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +403.1%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of $1.99, $1.08 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.12 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.56 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nutrien warns shareholders about below-market mini-tender offer
- Venu Holding enters $250 million at-the-market stock offering agreement
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
